Harmony Biosciences Q3 revenue $160.3M (+37% YoY); GAAP EPS $0.63, non-GAAP $0.97; Board authorizes $200M buyback

Harmony Biosciences Holdings, Inc.

2023-Q3 EPS reported $1.68 revenue$413,610,000

Net product revenue $160.3M (+37% YoY); average WAKIX patients ~5,800 (+350 sequentially).
GAAP net income $38.5M ($0.63 EPS); non-GAAP adjusted net income $58.8M ($0.97 EPS).
Board authorized new $200M share repurchase program, replacing $125M prior program.
Company continues to pursue idiopathic hypersomnia indication; expanded pipeline via Zynerba acquisition (Zygel for Fragile X).
Repurchased ~1.4M shares for $50M in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.